Abstract
Hartman K, Block A, et al (
Two placebo-controlled double-blind studies were undertaken to evaluate the therapeutic efficacy of the paramunity inducer, Baypamun(R) in FeLV-infected cats. In the first study, 120 cats were split into two groups, 60 received Baypamun(R) according to company instructions over a 7 week period and 60 a placebo. Remission of viremia occurred in 12% and 7% of the cats respectively, which was not statistically significant. In the second study, 30 naturally infected cats were treated in a placebo-controlled double-blind trial. Using a variety of immunological, clinical, laboratory, and virological parameters, no statistically significant differences could be demonstrated between Baypamun(R) and placebo application.